Subgroup analyses according to treatment modality showed that in HD patients, higher TNF‐α levels were significantly associated with an increased risk of sarcopenia (crude OR = 1.33; 95% CI: 1.17–1.52; p < 0.001; Figure 5), while no significant association was observed in NDD‐CKD patients. Here, TNF is linked to Neurodevelopmental delay.